I-Mab (NBP) Competitors

$1.82 -0.10 (-5.00%)

As of 03:56 PM Eastern

NBP vs. AKTS, ALVO, PHAT, SDGR, and CRON

Should you buy I-Mab stock or one of its competitors? MarketBeat compares I-Mab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with I-Mab include Aktis Oncology (AKTS), Alvotech (ALVO), Phathom Pharmaceuticals (PHAT), Schrodinger (SDGR), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.

How does I-Mab compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and I-Mab (NASDAQ:NBP) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Aktis Oncology had 5 more articles in the media than I-Mab. MarketBeat recorded 7 mentions for Aktis Oncology and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.93 beat Aktis Oncology's score of -0.16 indicating that I-Mab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology has higher revenue and earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	161.06	N/A	N/A	N/A
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
I-Mab	N/A	N/A	N/A

Aktis Oncology presently has a consensus target price of $32.00, suggesting a potential upside of 63.32%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 393.42%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aktis Oncology and I-Mab tied by winning 4 of the 8 factors compared between the two stocks.

How does I-Mab compare to Alvotech?

I-Mab (NASDAQ:NBP) and Alvotech (NASDAQ:ALVO) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

I-Mab presently has a consensus price target of $9.00, suggesting a potential upside of 393.42%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 125.19%. Given I-Mab's higher possible upside, equities research analysts clearly believe I-Mab is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

I-Mab has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

In the previous week, Alvotech had 6 more articles in the media than I-Mab. MarketBeat recorded 8 mentions for Alvotech and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.93 beat Alvotech's score of 0.24 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.4% of I-Mab shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

I-Mab has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. I-Mab's return on equity of 0.00% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Alvotech	-14.36%	-11.92%	-7.58%

Alvotech has higher revenue and earnings than I-Mab. Alvotech is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
Alvotech	$588.90M	1.73	$27.92M	-$0.25	N/A

Summary

I-Mab beats Alvotech on 9 of the 14 factors compared between the two stocks.

How does I-Mab compare to Phathom Pharmaceuticals?

I-Mab (NASDAQ:NBP) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

I-Mab currently has a consensus price target of $9.00, suggesting a potential upside of 393.42%. Phathom Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 110.00%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

I-Mab has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

I-Mab has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 2 mentions for I-Mab. Phathom Pharmaceuticals' average media sentiment score of 1.07 beat I-Mab's score of 0.93 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phathom Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.4% of I-Mab shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

I-Mab has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
Phathom Pharmaceuticals	$175.11M	5.42	-$221.25M	-$2.12	N/A

Summary

I-Mab beats Phathom Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does I-Mab compare to Schrodinger?

I-Mab (NASDAQ:NBP) and Schrodinger (NASDAQ:SDGR) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

I-Mab has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

I-Mab has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. I-Mab's return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Schrodinger	-40.61%	-30.85%	-15.32%

In the previous week, Schrodinger had 4 more articles in the media than I-Mab. MarketBeat recorded 6 mentions for Schrodinger and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.93 beat Schrodinger's score of 0.53 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab currently has a consensus target price of $9.00, indicating a potential upside of 393.42%. Schrodinger has a consensus target price of $20.25, indicating a potential upside of 69.54%. Given I-Mab's higher probable upside, research analysts clearly believe I-Mab is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

I-Mab has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
Schrodinger	$255.87M	3.45	-$103.26M	-$1.41	N/A

38.4% of I-Mab shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

I-Mab beats Schrodinger on 9 of the 15 factors compared between the two stocks.

How does I-Mab compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cronos Group has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

In the previous week, Cronos Group had 13 more articles in the media than I-Mab. MarketBeat recorded 15 mentions for Cronos Group and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.93 beat Cronos Group's score of 0.85 indicating that I-Mab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. I-Mab's return on equity of 0.00% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.14%	-1.26%	-1.20%
I-Mab	N/A	N/A	N/A

Cronos Group has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	6.76	-$9.45M	$0.01	263.50
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A

Cronos Group presently has a consensus target price of $2.30, indicating a potential downside of 12.71%. I-Mab has a consensus target price of $9.00, indicating a potential upside of 393.42%. Given I-Mab's higher possible upside, analysts clearly believe I-Mab is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

I-Mab beats Cronos Group on 8 of the 15 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBP vs. The Competition

Export

Metric	I-Mab	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$211.06M	$2.92B	$4.19B	$12.32B
Dividend Yield	N/A	15.20%	6.42%	5.35%
P/E Ratio	-5.07	13.15	22.71	25.37
Price / Sales	N/A	1,891.79	156.17	73.28
Price / Cash	N/A	26.88	53.46	56.33
Price / Book	0.91	4.20	39.09	6.93
Net Income	-$46.27M	-$42.51M	$113.55M	$333.88M
7 Day Performance	-17.09%	-0.49%	2.97%	0.33%
1 Month Performance	-29.85%	1.93%	4.88%	2.11%
1 Year Performance	N/A	17.18%	16.68%	33.31%

I-Mab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBP I-Mab	3.6907 of 5 stars	$1.82 -5.0%	$9.00 +393.4%	N/A	$211.06M	N/A	N/A	380
AKTS Aktis Oncology	1.6747 of 5 stars	$18.57 -1.4%	$32.00 +72.3%	N/A	$991.80M	$6.50M	N/A	76	Earnings Report Analyst Forecast
ALVO Alvotech	3.3048 of 5 stars	$3.26 +1.9%	$7.60 +133.1%	-67.3%	$983.90M	$588.90M	N/A	1,460
PHAT Phathom Pharmaceuticals	2.8803 of 5 stars	$12.16 -0.6%	$25.00 +105.6%	+301.5%	$969.83M	$204.89M	N/A	110
SDGR Schrodinger	3.089 of 5 stars	$13.13 -1.1%	$20.50 +56.1%	-47.2%	$969.32M	$254.91M	N/A	790	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBP) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I-Mab (NBP) Competitors

NBP vs. AKTS, ALVO, PHAT, SDGR, and CRON

How does I-Mab compare to Aktis Oncology?

Summary

How does I-Mab compare to Alvotech?

Summary

How does I-Mab compare to Phathom Pharmaceuticals?

Summary

How does I-Mab compare to Schrodinger?

Summary

How does I-Mab compare to Cronos Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

I-Mab (NBP) Competitors

NBP vs. AKTS, ALVO, PHAT, SDGR, and CRON

How does I-Mab compare to Aktis Oncology?

Does the media favor AKTS or NBP?

Which has better valuation and earnings, AKTS or NBP?

Is AKTS or NBP more profitable?

Do analysts prefer AKTS or NBP?

Do insiders and institutionals have more ownership in AKTS or NBP?

Summary

How does I-Mab compare to Alvotech?

Do analysts recommend NBP or ALVO?

Which has more volatility and risk, NBP or ALVO?

Does the media favor NBP or ALVO?

Do insiders and institutionals hold more shares of NBP or ALVO?

Is NBP or ALVO more profitable?

Which has better valuation & earnings, NBP or ALVO?

Summary

How does I-Mab compare to Phathom Pharmaceuticals?

Do analysts rate NBP or PHAT?

Is NBP or PHAT more profitable?

Which has more volatility & risk, NBP or PHAT?

Does the media prefer NBP or PHAT?

Do institutionals & insiders believe in NBP or PHAT?

Which has stronger valuation and earnings, NBP or PHAT?

Summary

How does I-Mab compare to Schrodinger?

Which has more risk and volatility, NBP or SDGR?

Is NBP or SDGR more profitable?

Does the media refer more to NBP or SDGR?

Do analysts rate NBP or SDGR?

Which has higher earnings and valuation, NBP or SDGR?

Do institutionals & insiders have more ownership in NBP or SDGR?

Summary

How does I-Mab compare to Cronos Group?

Do institutionals and insiders have more ownership in CRON or NBP?

Which has more volatility & risk, CRON or NBP?

Does the media favor CRON or NBP?

Is CRON or NBP more profitable?

Which has stronger valuation & earnings, CRON or NBP?

Do analysts prefer CRON or NBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools